Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 65 articles:
HTML format
Text format



Single Articles


    November 2017
  1. BOON D, Redd AD, Layendecker O, Engle R, et al
    Hepatitis E virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda.
    J Infect Dis. 2017 Nov 23. pii: 4653785. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. ROSENBERG BR, Freije CA, Imanaka N, Chen ST, et al
    Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. YANG HC, Shih YF, Liu CJ
    Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  5. SU TH, Kao JH
    Unmet Needs in Clinical and Basic Hepatitis B Virus Research.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  6. TSENG TC, Huang LR
    Immunopathogenesis of Hepatitis B Virus.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  7. WU D, Ning Q
    Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  8. LIU CJ, Kao JH
    NOhep: Toward Global Control of Hepatitis B Virus Infection-An Introduction.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  9. CHOI J, Lim YS
    Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  10. BUTI M, Riveiro-Barciela M, Esteban R
    Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  11. CHEN HL, Wen WH, Chang MH
    Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  12. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  13. CHANG Y, Choe WH, Sinn DH, Lee JH, et al
    Nucleos(t)ide Analogue Treatment for Adult Patients with HBeAg-positive Chronic Infection with Genotype C Hepatitis B Virus: A Nationwide Real-life Study.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. TAI CS, Wu JF, Chen HL, Ni YH, et al
    The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
    J Infect Dis. 2017;216:662-669.
    PubMed     Text format     Abstract available


    August 2017
  15. BOEIJEN LL, Montanari NR, de Groen RA, van Oord GW, et al
    Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy.
    J Infect Dis. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. HEIMER R, Binka M, Koester S, Grund JC, et al
    Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


    April 2017
  18. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  19. VAN DER REE MH, Jansen L, Kruize Z, van Nuenen AC, et al
    Plasma microRNA levels are associated with HBeAg status and treatment response in chronic hepatitis B patients.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. CHI H, Hansen BE, Guo S, Zhang NP, et al
    Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    J Infect Dis. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. CHEN GJ, Lin KY, Hung CC, Chang SC, et al
    Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  22. WANG L, Wen J, Gao F, Hao H, et al
    Hepatitis E virus-associated neurological injury in China.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  23. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  24. HAN Y, Gu L, Liu J, Li X, et al
    Association of mutations in TLR2 signaling genes with fulminant form of hepatitis B related acute liver failure.
    J Infect Dis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. ZHOU X, Huang F, Xu L, Lin Z, et al
    Hepatitis E virus infects neurons and brains.
    J Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


    January 2017
  26. CAO J, Chi H, Yu T, Li Z, et al
    Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    J Infect Dis. 2017 Jan 19. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  27. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A Virus Endemic Circulation in Israel Despite Universal Toddler Vaccination Since 1999 and Low Clinical Incidence in All Age Groups.
    J Infect Dis. 2016 Dec 24. doi: 10.1093.
    PubMed     Text format    


  28. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
    J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. CHEN MH, Chen MH, Liu CY, Tsai CY, et al
    Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment.
    J Infect Dis. 2016 Dec 23. pii: jiw606. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  31. SCHIRDEWAHN T, Grabowski J, Sekyere SO, Bremer B, et al
    The third signal cytokine IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  32. HALLAGER S, Brehm Christensen P, Ladelund S, Rye Clausen M, et al
    Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population - a Danish cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  33. HENGST J, Falk CS, Schlaphoff V, Deterding K, et al
    DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  34. WANG L, Wiener J, Bulterys M, Wei X, et al
    Hepatitis B Viral Load Response to two Antiviral Regimens (Tenofovir/Lamivudine vs Lamivudine) in HIV and HBV Co-Infected Pregnant Women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  35. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  36. HONER ZU SIEDERDISSEN C, Rinker F, Maasoumy B, Wiegand SB, et al
    Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  37. MAYORGA O, Buhler S, Jaeger VK, Bally S, et al
    Single dose hepatitis A immunisation: 7.5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  38. RODRIGO C, Eltahla AA, Bull RA, Grebely J, et al
    Historical trends in the hepatitis C virus epidemics in North America and Australia.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  39. KOSTADINOVA L, Shive C, Judge C, Zebrowski E, et al
    During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  40. MARKOWITZ M, Deren S, Cleland C, La Mar M, et al
    Chronic hepatitis C infection and the pro-inflammatory effects of injection drug use.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  41. ZEREMSKI M, Dimova RB, Pillardy J, de Jong YP, et al
    Fibrosis Progression in Patients with Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  42. FIERER DS
    The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression of Hepatitis C-infected Patients.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  43. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Text format     Abstract available


    June 2016
  44. CHEN YI MEI SL, Burchell J, Skinner N, Millen R, et al
    Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  45. BEHRENDT P, Bremer B, Todt D, Brown RJ, et al
    Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  46. SHILAIH M, Marzel A, Scherrer AU, Braun DL, et al
    Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  47. SIMONS BC, Spradling PR, Bruden DJ, Zanis C, et al
    A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B cellular immunity despite loss of antibody against hepatitis B surface antigen.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  48. HONDA M, Shirasaki T, Terashima T, Kawaguchi K, et al
    Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    J Infect Dis. 2016;213:1096-106.
    PubMed     Text format     Abstract available


    March 2016
  49. MOQUEET N, Cooper C, Gill J, Hull M, et al
    Responder Interferon Lambda genotypes are associated with higher risk of liver fibrosis in HIV-Hepatitis C Virus Co-infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  50. ARAGRI M, Alteri C, Battisti A, Di Carlo D, et al
    Multiple HBV Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  51. EVANS TI, Li H, Schafer JL, Klatt NR, et al
    SIV-induced Translocation of Bacterial Products in the Liver Mobilizes Myeloid Dendritic and Natural Killer Cells Associated With Liver Damage.
    J Infect Dis. 2016;213:361-9.
    PubMed     Text format     Abstract available


    January 2016
  52. VAN DAMME P
    Long-term Protection After Hepatitis B Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  53. BRUCE MG, Bruden D, Hurlburt D, Zanis C, et al
    Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  54. SAKIANI S, Koh C, Heller T
    Reply to Tennant and Post.
    J Infect Dis. 2016;213:325-6.
    PubMed     Text format    


  55. PIROTH L, Launay O, Michel ML, Bourredjem A, et al
    Vaccination against hepatitis B virus in HIV-1 infected patients with isolated anti-HBc: the ANRS HB EP03 CISOVAC prospective study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  56. MASTRO TD, Morrison CS, Hamilton CD
    Determining Hepatitis C Virus Incidence in Populations: an Important Tool for Epidemic Control.
    J Infect Dis. 2016.
    PubMed     Text format    


  57. PATEL EU, Cox AL, Mehta SH, Boon D, et al
    Hepatitis C IgG antibody avidity as a biomarker to estimate population-level incidence.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    December 2015
  58. MATTHEWS PC, Carlson JM, Beloukas A, Malik A, et al
    HLA-A is a Predictor of Hepatitis B e-Antigen Status in HIV-positive African Adults.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    November 2015
  59. SWANSON S, Ma Y, Scherzer R, Huhn G, et al
    Association of HIV, HCV and Liver Fibrosis Severity with the Enhanced Liver Fibrosis Score.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  60. SVAROVSKAIA ES, Gane E, Dvory-Sobol H, Martin R, et al
    L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  61. LIANG KH, Hsu CW, Chang ML, Chen YC, et al
    Peginterferon is superior to nucleos(t)ide analogs for prevention of hepatocellular carcinoma in chronic hepatitis B.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  62. OLMSTEAD AD
    Digging Deeper into Hepatitis C Virus Outbreaks.
    J Infect Dis. 2015.
    PubMed     Text format    


  63. CAMPO DS, Xia GL, Dimitrova Z, Lin Y, et al
    Accurate genetic detection of hepatitis C virus transmissions in outbreak settings.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  64. LY KN, Klevens RM, Jiles RB
    Reply to Jones.
    J Infect Dis. 2015.
    PubMed     Text format    


    July 2015
  65. HERMANS LE, Svicher V, Pas SD, Salpini R, et al
    Combined Analysis of the Prevalence of drug Resistant HBV in antiviral therapy Experienced patients in Europe (CAPRE).
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: